| Literature DB >> 26409464 |
Roeltje R Maas1, Adela Della Marina2, Arjan P M de Brouwer3,4, Ron A Wevers5, Richard J Rodenburg1, Saskia B Wortmann6.
Abstract
SUCLA2 encodes for a subunit of succinyl-coenzyme A synthase, the enzyme that reversibly synthesises succinyl-coenzyme A and ATP from succinate, coenzyme A and ADP in the Krebs cycle. Disruption of SUCLA2 function can lead to mitochondrial DNA depletion. Patients with a SUCLA2 mutation present with a rare but distinctive deafness-dystonia syndrome. Additionally, they exhibit elevated levels of the characteristic biochemical markers: methylmalonate, C4-dicarboxylic carnitine and lactate are increased in both plasma and urine. Thus far, eight different disease-causing SUCLA2 mutations, of which six missense mutations and two splice site mutations, have been described in the literature. Here, we present the first patient with an intragenic deletion in SUCLA2 and review the patients described in literature.Entities:
Keywords: 3-Methylglutaconic aciduria; Hearing impairment; Mitochondrial DNA depletion; Movement disorder; SUCLG1
Year: 2015 PMID: 26409464 PMCID: PMC4864773 DOI: 10.1007/8904_2015_464
Source DB: PubMed Journal: JIMD Rep ISSN: 2192-8304